Webinar Replay: Turning Tragedy into Triumph: How a Family Uses Impact Investment and Philanthropic Initiatives in Precision Medicine to Advance New Cures
The UHNW Institute recently hosted a virtual webinar titled ‘Turning Tragedy into Triumph: Using Impact Investment and Philanthropic Initiatives in Precision Medicine to Advance New Cures.’ The webinar was moderated by Edward Marshall, Global Head of Family Office and HNW at Dentons, and featured speakers from various philanthropic, research, and investing endeavors.
UHNW families have the potential to bring tremendous financial, social, intellectual, and human capital to the table to solve significant problems, including global health issues. This webinar, which combined three domains of family wealth, explored a real-world case study: Project ALS. Project ALS seeks to find and fund a cure for amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease.
Some of the specific topics discussed during this webinar included:
- How families are addressing global health issues and how this approach is evolving.
- The role impact investments can play in advancing new cures.
- Ways advisors can help clients maximize their impact through charitable giving.
- Challenges that are emerging in the impact investing space and how to address them.
- Overviews of Project ALS and ProJenX, showcasing how one family made a significant impact.
- Concrete steps that families can take to support philanthropic initiatives for diseases that personally affect them.
Even if you were unable to attend this live discussion, you can still gain the knowledge needed to assist families in finding measurable meaning and purpose in charitable giving and investments by watching the webinar replay. The full video replay of this live webinar is available for UHNW Institute members in the Resource Library here. We invite members to ask questions, discuss this topic further and interact with the speakers here in the Community Forum.
Thank you to our speakers:
Edward Marshall, Global Head of Family Office and High Net Worth, Dentons
Stan Abel, President & CEO, ProJenX
Valerie Estess, Co-Founder, Project ALS
Erin Fleming, VP Research & Development, ProJenX
John Prufeta, Founder, CEO & General Partner, Medical Excellence Capital; Co-Founder, ProJenX
Drew Rabe, Managing Director, Arabella Advisors
